Aims This study investigated the possible association between hs-CRP as well as hs-CRP changes and rhythm outcome after AF catheter ablation. Methods We studied 68 consecutive patients with AF undergoing catheter ablation. hs-CRP levels were measured using commercially available assays before and 6 months after catheter ablation. Serial 7-day Holter ECGs were used to detect AF recurrences. Results Early AF recurrence (ERAF, within one week) was observed in 38%, while late AF recurrence (LRAF, between 3 and 6 months) occurred in 18% of the patients. None of the baseline clinical or echocardiographic variables was predictive of ERAF or LRAF. Baseline hs-CRP measured 2.07±1.1 μg/ml and was not associated with ERAF and LRAF. At 6 months, hs-CRP levels were comparable with baseline values (2.14±1.19 μg/ml, p = 0.409) and were also not related with LRAF. However, patients with LRAF showed an hs-CRP increase from 2.03±0.61 to 2.62±1.52 μg/ml (p = 0.028). Patients with an hs-CRP change in the upper tertile (>0.2 μg/ml) had LRAF in 32% as opposed to 11% (p = 0.042) in patients in the lower (<？0.3 μg/ml) or intermediate (？0.3–0.2 μg/ml) tertile. Conclusions Changes in hs-CRP but not baseline hs-CRP are associated with rhythm outcome after AF catheter ablation. This finding points to a link between an inflammatory response and AF recurrence in this setting.
References
[1]
Boos CJ, Anderson RA, Lip GY (2006) Is atrial fibrillation an inflammatory disorder? Eur Heart J 27: 136–149.
[2]
Issac TT, Dokainish H, Lakkis NM (2007) Role of inflammation in initiation and perpetuation of atrial fibrillation: a systematic review of the published data. J Am Coll Cardiol 50: 2021–2028.
[3]
Kourliouros A, Savelieva I, Kiotsekoglou A, Jahangiri M, Camm J (2009) Current concepts in the pathogenesis of atrial fibrillation. Am Heart J 157: 243–252.
[4]
Chung MK, Martin DO, Sprecher D, Wazni O, Kanderian A, et al. (2001) C-reactive protein elevation in patients with atrial arrhythmias: inflammatory mechanisms and persistence of atrial fibrillation. Circulation 104: 2886–2891.
[5]
Anderson JL, Allen Maycock CA, Lappe DL, Crandall BG, Horne BD, et al. (2004) Frequency of elevation of C-reactive protein in atrial fibrillation. Am J Cardiol 94: 1255–1259.
[6]
Engelmann MD, Svendsen JH (2005) Inflammation in the genesis and perpetuation of atrial fibrillation. Eur Heart J 26: 2083–2092.
[7]
Liu T, Li G, Li L, Korantzopoulos P (2007) Association between C-reactive protein and recurrence of atrial fibrillation after successful electrical cardioversion: a meta-analysis. J Am Coll Cardiol 49: 1642–1648.
[8]
Malouf JF, Kanagala R, Al Atawi FO, Rosales AG, Davison DE, et al. (2005) High sensitivity C-reactive protein: a novel predictor for recurrence of atrial fibrillation after successful cardioversion. J Am Coll Cardiol 46: 1284–1287.
[9]
Henningsen KM, Therkelsen SK, Bruunsgaard H, Krabbe KS, Pedersen BK, et al. (2009) Prognostic impact of hs-CRP and IL-6 in patients with persistent atrial fibrillation treated with electrical cardioversion. Scand J Clin Lab Invest 69: 425–432.
[10]
Psychari SN, Apostolou TS, Sinos L, Hamodraka E, Liakos G, et al. (2005) Relation of elevated C-reactive protein and interleukin-6 levels to left atrial size and duration of episodes in patients with atrial fibrillation. Am J Cardiol 95: 764–767.
[11]
Watanabe T, Takeishi Y, Hirono O, Itoh M, Matsui M, et al. (2005) C-reactive protein elevation predicts the occurrence of atrial structural remodeling in patients with paroxysmal atrial fibrillation. Heart Vessels 20: 45–49.
[12]
Lin YJ, Tsao HM, Chang SL, Lo LW, Tuan TC, et al. (2010) Prognostic implications of the high-sensitive C-reactive protein in the catheter ablation of atrial fibrillation. Am J Cardiol 105: 495–501.
[13]
Narducci ML, Pelargonio G, Dello Russo A, Casella M, Biasucci LM, et al.. (2011) Role of tissue C-reactive protein in atrial cardiomyocytes of patients undergoing catheter ablation of atrial fibrillation: pathogenetic implications. Europace 29.
[14]
Venugopal SK, Devaraj S, Yuhanna I, Shaul P, Jialal I (2002) Demonstration that C-reactive protein decreases eNOS expression and bioactivity in human aortic endothelial cells. Circulation 106: 1439–1441.
[15]
Joshi MS, Tong L, Cook AC, Schanbacher BL, Huang H, et al.. (2012) Increased myocardial prevalence of C-reactive protein in human coronary heart disease: direct effects on microvessel density and endothelial cell survival. Cardiovasc Pathol Epub ahead of print.
[16]
Calkins H, Kuck KH, Cappato R, Brugada J, Camm AJ, et al. (2012) HRS/EHRA/ECAS Expert Consensus Statement on Catheter and Surgical Ablation of Atrial Fibrillation: recommendations for patient selection, procedural techniques, patient management and follow-up, definitions, endpoints, and research trial design. Europace 14: 528–606.
[17]
McCabe JM, Smith LM, Tseng ZH, Badhwar N, Lee BK, et al. (2008) Protracted CRP elevation after atrial fibrillation ablation. Pacing Clin Electrophysiol 31: 1146–1151.
[18]
Stein A, Wessling G, Deisenhofer I, Busch G, Steppich B, et al. (2008) Systemic inflammatory changes after pulmonary vein radiofrequency ablation do not alter stem cell mobilization. Europace 10: 444–449.
[19]
Lellouche N, Sacher F, Wright M, Nault I, Brottier J, et al. (2009) Usefulness of C-reactive protein in predicting early and late recurrences after atrial fibrillation ablation. Europace 11: 662–664.
[20]
Liu J, Fang PH, Dibs S, Hou Y, Li XF, et al.. (2010) High-Sensitivity C-Reactive Protein as a Predictor of Atrial Fibrillation Recurrence after Primary Circumferential Pulmonary Vein Isolation. Pacing Clin Electrophysiol 1540–8159.
[21]
Letsas KP, Weber R, Burkle G, Mihas CC, Minners J, et al. (2009) Pre-ablative predictors of atrial fibrillation recurrence following pulmonary vein isolation: the potential role of inflammation. Europace 11: 158–163.
[22]
Rotter M, Jais P, Vergnes MC, Nurden P, Takahashi Y, et al. (2006) Decline in C-reactive protein after successful ablation of long-lasting persistent atrial fibrillation. J Am Coll Cardiol 47: 1231–1233.
[23]
Eitel C, Hindricks G, Sommer P, Gaspar T, Kircher S, et al. (2009) Circumferential pulmonary vein isolation and linear left atrial ablation as a single-catheter technique to achieve bidirectional conduction block: the pace-and-ablate approach. Heart Rhythm 7: 157–164.
[24]
Husser D, Adams V, Piorkowski C, Hindricks G, Bollmann A (2010) Chromosome 4q25 variants and atrial fibrillation recurrence after catheter ablation. J Am Coll Cardiol 55: 747–753.
[25]
Aviles RJ, Martin DO, Apperson-Hansen C, Houghtaling PL, Rautaharju P, et al. (2003) Inflammation as a risk factor for atrial fibrillation. Circulation 108: 3006–3010.
[26]
Kallergis EM, Manios EG, Kanoupakis EM, Mavrakis HE, Kolyvaki SG, et al. (2008) The role of the post-cardioversion time course of hs-CRP levels in clarifying the relationship between inflammation and persistence of atrial fibrillation. Heart 94: 200–204.
[27]
Acevedo M, Corbalan R, Braun S, Pereira J, Navarrete C, et al. (2006) C-reactive protein and atrial fibrillation: “evidence for the presence of inflammation in the perpetuation of the arrhythmia”. Int J Cardiol 108: 326–331.
[28]
Frustaci A, Chimenti C, Bellocci F, Morgante E, Russo MA, et al. (1997) Histological substrate of atrial biopsies in patients with lone atrial fibrillation. Circulation 96: 1180–1184.
[29]
Nakamura Y, Nakamura K, Fukushima-Kusano K, Ohta K, Matsubara H, et al. (2003) Tissue factor expression in atrial endothelia associated with nonvalvular atrial fibrillation: possible involvement in intracardiac thrombogenesis. Thromb Res 111: 137–142.
[30]
Korantzopoulos P, Kolettis TM, Kountouris E, Siogas K, Goudevenos JA (2005) Variation of inflammatory indexes after electrical cardioversion of persistent atrial fibrillation. Is there an association with early recurrence rates? Int J Clin Pract 59: 881–885.
